News

News 01.05.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...

News 30.04.2026 The genetically validated inflammasome pathway in Inflammatory Bowel Disease (IBD) offers the opportunity to develop novel drugs beyond the pathways targeted today. Building on these premises, Mabylon has secured Eurostars funding for ASCEND, a €1.46M collaborative project to advance MY012, a monoclonal antibody targeting extracellular ASC within the inflammasome pathway. ASCEND brings...

News 29.04.2026 DINAMIQS, a Siegfried company (SIX: SFZN) today announced that it has received a manufacturing and testing license from Swissmedic for viral vector cGMP production. With this approval, DINAMIQS is authorized to manufacture and release genomic medicines under GMP conditions, marking an important milestone in expanding Siegfried’s capabilities in advanced therapies...

News 24.04.2026 CAMBRIDGE, Mass. – April 23, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid...

News 20.04.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters...